CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis

Many publications have evaluated the correlation between Cytochrome P450 1A1 (CYP1A1) Ile462Val polymorphism and cervical cancer risk, but the results remain inconclusive. To provide a more robust estimate of this effect, a meta-analysis was carried out. We systematically searched PubMed, Embase and CBM databases for studies published before May 2012. The association between CYP1A1 Ile462Val polymorphism and cervical cancer risk was assessed by calculating pooled odds ratios (OR) with its 95 % confidence intervals (95 % CI). On the basis of our inclusion criteria, ten studies with a total of 2,423 individuals were included in the meta-analysis. Overall, CYP1A1 Ile462Val polymorphism was associated with increased risk of cervical cancer (Val versus Ile, OR = 1.43; 95 % CI, 1.03–1.97; ValVal versus IleIle, OR = 2.43; 95 % CI, 1.19–4.95; ValVal+ValIle versus IleIle, OR = 1.59; 95 % CI, 1.00–2.53). Ethnic subgroup analyses showed a significant association was found in Caucasians (Val versus Ile, OR = 2.03; 95 % CI, 1.17–3.51; ValVal versus IleIle, OR = 2.74; 95 % CI, 1.30–5.75; ValVal+ValIle versus IleIle, OR = 2.50; 95 % CI, 1.33–4.70), but not in Asians. In conclusion, this meta-analysis suggests that CYP1A1 Ile462Val polymorphism plays an important role in susceptibility to cervical cancer. Further studies with large sample size and careful design need performing to identify this association more comprehensively.